Zydus Cadila, subsidiary of Cadila Healthcare on Friday afternoon announced receiving Restricted Emergency Use Approval from the Drug Controller General of India (DCGI) for the use of ‘Virafin’, a medicine used for treating moderate COVID-19 infection in adults.
A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID, Virafin will help patients recover faster and avoid much of the complications.
Virafin will be available on the prescription of medical specialist for use in hospital/institutional setup.
In the multicentric trial conducted in 20-25 centers across India, Virafin had shown lesser need for supplemental oxygen, clearly indicating that it was able to control respiratory distress and failure which has been one of the major challenges in treating COVID-19. The drug has also shown efficacy against other viral infections.
On Friday itself, the stock price had hit a new high at Rs.577.65 and closed at Rs.571.20 and today, it opened at a new high at Rs.605, wherein profit booking came in and the stock is now trading at Rs.577 levels.